

Suspected cancer committee 1 minutes

- **Principle** – record the Committee meeting attendance, running, discussions
- **Links to include** – none
- **Attachments to include** – none
- **Info to include** –guideline title; meeting date/location; status of minutes (draft/confirmed); attendees; observers; apologies; agenda items and related discussions; declarations of interest; date of next meeting

Suspected cancer recognition and referral

Committee meeting 1

Date: 07/10/2025

Location: Zoom

Minutes: Final

Committee members present:	
Britta Stordal (Chair)	Present for notes 1 – 7
Emily Acomb	Present for notes 1 – 7
Aqsa Ahmed	Present for notes 1 – 6
Maria Ahmed	Present for notes 1 – 7
Nicola Aloysius	Present for notes 1 – 7
Lesley Christie	Present for notes 1 – 7
Stephen Hanna	Present for notes 1 – 7
Deevia Kotecha	Present for notes 1 – 7
Diana Marcus	Present for notes 1 – 7
Rakhi Raj	Present for notes 1 – 7
Susan Ritchie	Present for notes 1 – 7
Meena Shenbaganandam	Present for notes 1 – 7

In attendance:		
Robby Richey	Topic Lead	Present for notes 1 – 7
Jeremy Braybrooke	Consultant Clinical Adviser	Present for notes 1 – 7
Lindsay Claxton	Health Economic Adviser	Present for notes 1 – 7
James Hawkins	Health Economic Adviser	Present for notes 1 – 7
James Jagroo	Senior Technical Analyst	Present for notes 1 – 7

Suspected cancer committee 1 minutes

Yolanda Martinez	Technical Analyst	Present for notes 1 – 7
Sarah Palombella	Senior Content Designer	Present for notes 1 – 7
Armina Paule	Technical Analyst	Present for notes 1 – 7
Eric Slade	Health Economic Adviser	Present for notes 1 – 4

Observers:

Sarah Case-Scott	Present for note 1
Rachel Gick	Present for notes 1 – 7
Tracy O'Regan	Present for notes 1 – 7
Eileen Taylor	Present for notes 1 – 7

Apologies:

Katherine Saxby	NICE Medicines Adviser
-----------------	------------------------

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the first meeting on Suspected cancer: recognition and referral. The Committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Reviewing the evidence, clinical and economic, for ovarian cancer.
- Reviewing the evidence, clinical and economic, for non-site-specific weight loss.
- Reviewing and drafting potential new recommendations and research recommendations.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the update to the NICE recommendations on Ovarian cancer and non-site-specific weight loss.

The Chair asked everyone to verbally declare any interests that have arisen since

Suspected cancer committee 1 minutes

the papers were shared. No new interests were declared.

Additionally, the Chair and a senior member of the Developer's team noted that none of the interests declared prior to the meeting prevented the attendees from fully participating.

3. Morning presentation and discussion – ovarian cancer

The Chair introduced James Jagroo (Senior Technical Analyst), Armina Paule (Technical Analyst) and Eric Slade (Health Economic Adviser). James first gave a presentation on NICE methods, discussing recommendation drafting, outlining the key goals for the committee and highlighting the differences in recommendation strength and the evidence needed to support each.

James was then followed by Armina who presented the up-to-date evidence on Ovarian cancer, specifically:

- Dual testing with serum CA125 and ultrasound scan compared to serum CA125 alone
- Age and serum CA125 thresholds for detection of suspected ovarian cancer in adults.

Eric then presented the economic evidence to underpin the cost-effectiveness of the discussed treatments.

The Committee then discussed the issues presented and the team took questions.

Finally, led by James and Armina, the Committee discussed possible recommendation changes that could be made to the existing recommendations on ovarian cancer in light of the presented evidence.

The Chair then thanked James, Armina and Eric for their presentations and moved on to the next agenda item

4. Afternoon presentation and discussion – Non-site-specific weight loss

The Chair introduced Yolanda Martinez (Technical Analyst) and Lindsay Claxton (Health Economic Adviser). Yolanda presented the up-to-date evidence on non-site-specific weight loss, specifically which age thresholds should unexplained weight loss be used to refer adults via a suspected cancer pathway.

As with the morning session, Lindsay then gave a brief presentation on the cost-effectiveness of pathway changes.

The Committee then discussed the issues presented and the team took questions

Suspected cancer committee 1 minutes

before moving on the drafting of updated recommendations.

The Chair then thanked Yolanda for her presentation and moved on to the final main agenda item

6. Editorial presentation

The Chair introduced Sarah Palombella (Senior Content Designer) who gave a brief presentation on her role as content designer, how she will work with the committee to draft clear recommendations and the editorial rules governing how NICE draft our recommendations.

7. Any other business

There were no further items to raise so the Chair thanked the committee and the NICE team for their time and work and closed the meeting.

Date of next meeting: 18/11/2025

Location of next meeting: Zoom